INM · InMed Pharmaceuticals Inc.
$1.51
+0.05 (+3.42%)
At close · Aug 4
Going-concern doubt
— flagged May 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. management has determined that the Company's liquidity condition raises substantial doubt about the Company's ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these financial statements.”View the 10-Q filed May 6, 2026
Market Cap
$4.84M
Shares
3.31M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John Bathery | director | Appointed | 2025-10-16 |
| Neil Klompas | director | Appointed | 2025-10-14 |
| Janet Grove | member of the Company's Board of Directors | Resigned | 2025-02-14 |